Biotech Values

[DewDiligence]

Good question; however, the SVR rate is only part of the story. If adding a DAA such as Telaprevir to the SoC could increase the SVR rate of patients with the CC gene variant even slightly while also shortening the duration of treatment by 24 weeks, I think it would be well worth it.